ArticleBMC pregnancy and childbirth2026
Reduced HSD17B1 expression in preeclampsia: integrated transcriptomic, summary Mendelian randomization, immune deconvolution, and experimental validation.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
background17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) is a key placental steroidogenic enzyme that converts estrone to estradiol. Prior studies have suggested that reduced placental or circulating HSD17B1 is associated with preeclampsia (PE), but its position within the broader transcriptomic landscape and its relationship to immune changes remain incompletely characterized.
methodsPlacental transcriptomic data from GSE75010 (77 controls and 80 PE placentas) were analyzed to identify differentially expressed genes (DEGs). Summary data-based Mendelian randomization (SMR) integrating eQTLGen cis-eQTL data with FinnGen preeclampsia summary statistics was then used to prioritize candidate genes. Immune cell infiltration was explored by CIBERSORT using the placental bulk transcriptomic matrix. Independent validation was performed in a clinical cohort comprising 96 women with PE and 96 normotensive pregnant controls by maternal plasma ELISA at 17-18 weeks of gestation and placental RT-qPCR at delivery.
resultsDEG analysis identified 207 genes (152 upregulated and 55 downregulated) in PE placentas. HSD17B1 was the single overlapping candidate prioritized by both DEG and SMR analyses, and genetically predicted higher HSD17B1 expression showed an inverse association with PE risk under nominal SMR significance criteria. In the validation cohort, plasma HSD17B1 was lower in women with PE than in controls, and placental HSD17B1 mRNA was also significantly reduced. Exploratory immune deconvolution showed altered proportions of plasma cells, CD8 T cells, regulatory T cells, resting CD4 memory T cells, resting mast cells, eosinophils, and neutrophils in PE placentas; HSD17B1 expression correlated with several of these subsets.
conclusionsHSD17B1 is consistently downregulated in PE across public placental transcriptomic data and an independent validation cohort. When interpreted together with prior literature on miR-210/miR-518c, ESRRG signaling, and trophoblast differentiation, these findings support HSD17B1 as a biologically plausible PE-associated marker. However, the present study does not establish whether reduced HSD17B1 is a cause or a consequence of PE, and the immune findings should be regarded as exploratory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.